Medtronic Hands Marinaro the Presidency While Closing MiniMed and Clearing Five Pacemakers
Published on 10/24/2026 at 15:31 | Editorial boerse-global.de
Medtronic has bundled more responsibility onto Michael Marinaro, naming him president while leaving his existing commercial and portfolio duties intact. The appointment, disclosed in a regulatory filing on 15 October, took effect on 14 October — a consolidation of authority rather than a change of role.
Marinaro's expanded title sits alongside a structural shift that is already complete. Medtronic has finished spinning off the MiniMed Group, which now operates as a standalone company, and it has wrapped up the associated exchange offer, taking its own shares in return for MiniMed stock.
A 5.4-fold oversubscribed swap
The scale of investor appetite for that swap is now clear. Medtronic exchanged its remaining 252,813,348 MiniMed shares through an offer that drew 5.4 times the demand needed to cover it. The oversubscription speaks to interest in the exchange itself, not to Medtronic's future operating performance — and the key point for investors is status: the transaction is finished, no longer pending.
Keeping the two developments apart matters. The Marinaro appointment concerns internal leadership at Medtronic; the spin-off changes the corporate structure. Nothing in the personnel move alone says anything extra about the economic consequences of the separation.
Should investors sell immediately? Or is it worth buying Medtronic?
Five pacemakers win CE marking
On the product front, Medtronic said Monday it had secured CE marking for its Vitalis portfolio. The clearance covers five pacemakers — ReSyncra CSP, Restoria CSP, Refina CSP, Effectra and Confirma — all designed to support stimulation of the body's own conduction system. The milestone is regulatory, spanning an entire product family rather than a single device, and should not be confused with clinical outcomes for other Medtronic products: a CE mark and registry data deliver different kinds of information.
Registry findings arrived Thursday, adding real-world experience with the Sphere-9 catheter and the PulseSelect PFA system. The APEX analysis tracked 1,050 patients with atrial fibrillation across 28 sites and recorded a major complication rate of 1.1%.
REAL PULSE, meanwhile, covered 1,160 patients and reported acute procedural success of 100%, with acute major complications at 0.09%. Both sets of figures concern atrial fibrillation. A separate analysis looked at ventricular tachycardia — a different patient group — where 46 patients produced 87% acute procedural success and an estimated 75% freedom from recurrence at six months.
Medtronic at a turning point? This analysis reveals what investors need to know now.
What the pieces add up to
Taken together, the picture is one of separate advances that do not substitute for one another: Marinaro's widened remit, a completed MiniMed separation, CE marking for Vitalis and fresh registry data. They offer concrete markers of organizational and operational progress — but on their own they are not proof of higher revenue or profit.
Ad
Medtronic Stock: New Analysis - 24 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
